Back to Search
Start Over
Peripheral T Cell Subpopulations as a Potential Surrogate Biomarker during Atezolizumab plus Bevacizumab Treatment for Hepatocellular Carcinoma.
- Source :
- Cancers; Apr2024, Vol. 16 Issue 7, p1328, 18p
- Publication Year :
- 2024
-
Abstract
- Simple Summary: In this study, we evaluated the status and dynamics of peripheral T cell subpopulations in hepatocellular carcinoma (HCC) patients receiving immune checkpoint blockade with atezolizumab plus bevacizumab (Atez/Bev) treatment and explored biomarkers that are predictive of therapeutic response. The results showed that a higher proportion of CD8+ central memory T cells at baseline is associated with tumor inflammation in HCC, as well as with longer progression-free survival in response to Atez/Bev treatment, especially in cases with an increased proportion of CD8+ effector memory T cells after 3 weeks. Our findings suggest that the peripheral T cell subpopulation can serve as a potential noninvasive biomarker predicting benefits from Atez/Bev treatment. The therapeutic benefits of the immunotherapeutic combination of atezolizumab and bevacizumab (Atez/Bev) in hepatocellular carcinoma (HCC) vary. Therapeutic biomarkers might help improve outcomes for HCC patients receiving Atez/Bev therapy. The role of systemic immune profiles in HCC progression also remains unclear. This study aimed to evaluate the status and dynamics of peripheral T cell subpopulations in HCC patients receiving Atez/Bev treatment and to explore biomarkers predictive of a therapeutic response. We enrolled 83 unresectable advanced HCC patients who commenced Atez/Bev treatment at our hospital between October 2020 and June 2022. Peripheral T cell subpopulations in peripheral blood mononuclear cells at baseline and 3 weeks post-treatment were investigated using flow cytometry and compared with those in control samples from 18 healthy individuals. We retrospectively analyzed the association between peripheral T cell subpopulation profiles and clinical outcomes. Baseline peripheral T cell subpopulations could be profiled in 70 patients with sufficient cell counts, among whom 3-week subpopulations could be evaluated in 51 patients. Multivariate analysis showed that a high baseline proportion of CD8+ central memory T (TCM) cells was independently associated with longer progression-free survival (PFS). Further, overall survival (OS) was significantly prolonged in patients with increased CD8+ effector memory T (TEM) cell proportions. In conclusion, TCM proportion at baseline might be a good indicator of the efficacy of Atez/Bev therapy. Furthermore, observation of increasing TEM proportions might be an early predictor of the potential clinical benefits of treatment. [ABSTRACT FROM AUTHOR]
- Subjects :
- THERAPEUTIC use of monoclonal antibodies
FLOW cytometry
T cells
PREDICTION models
MONONUCLEAR leukocytes
RESEARCH funding
BEVACIZUMAB
IMMUNOTHERAPY
FISHER exact test
TUMOR markers
RETROSPECTIVE studies
MULTIVARIATE analysis
IMMUNOLOGIC memory
MANN Whitney U Test
QUANTITATIVE research
GENE expression
IMMUNOHISTOCHEMISTRY
KAPLAN-Meier estimator
LOG-rank test
LONGITUDINAL method
IMMUNE checkpoint inhibitors
COMBINED modality therapy
DRUG efficacy
PROGRESSION-free survival
COMPARATIVE studies
DATA analysis software
INFLAMMATION
HEPATOCELLULAR carcinoma
OVERALL survival
PROPORTIONAL hazards models
REGRESSION analysis
Subjects
Details
- Language :
- English
- ISSN :
- 20726694
- Volume :
- 16
- Issue :
- 7
- Database :
- Complementary Index
- Journal :
- Cancers
- Publication Type :
- Academic Journal
- Accession number :
- 176597973
- Full Text :
- https://doi.org/10.3390/cancers16071328